Buoyed by the smart set of earnings, the stock surged by 6.48 per cent to end at Rs 625.65 on BSE. Intra-day, it advanced by 7.39 per cent to Rs 631.
At NSE, shares of the company jumped 5.94 per cent to close at Rs 625.10.
Following the rally, the company's market valuation rose by Rs 718.5 crore to Rs 11,794.50 crore.
Alembic Pharmaceuticals today reported nearly four-fold jump in its consolidated net profit to Rs 269.49 crore for the December quarter, mainly on account of robust sales in overseas markets.
Consolidated total income from operations rose to Rs 921.73 crore in the quarter under review as against Rs 511.78 crore in the year-ago period.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%